Olezarsen – Talk Bio

Actionable Insights Powered by AI

FDA Approves Ionis’s TRYNGOLZA for Familial Chylomicronemia Syndrome, a Rare Metabolic Disorder

4 months ago talkbio0Tagged Approved, Familial chylomicronemia syndrome, Metabolic Diseases, Olezarsen, TRYNGOLZA, United States Food and Drug Administration

FDA approval, Ionis Pharmaceuticals, TRYNGOLZA, olezarsen, familial chylomicronemia syndrome (FCS), rare metabolic disorder

Arrowhead Pharmaceuticals Highlights Key Pancreatitis Data from Phase 3 Lipid Disease Study to Distinguish Itself from Ionis

8 months ago talkbio0Tagged Arrowhead, Familial chylomicronemia syndrome, Hypertriglyceridemia ( SHTG, Ionis Pharmaceuticals, Olezarsen, Pancreatitis, Acute, Plozasiran, RNA Interference, Triglycerides

Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Plozasiran, Olezarsen, Severe Hypertriglyceridemia (SHTG), Familial Chylomicronemia Syndrome (FCS), Acute Pancreatitis, RNAi Therapy, Triglyceride Reduction